Application of proteomics in non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease with diverse pathological features. Clinical proteomics allows the discovery of molecular markers and new therapeutic targets for this most prevalent type of lung cancer. Some of them may be used to detect early lung cancer, while others may serve as predictive markers of resistance to different therapies. Therapeutic targets and prognostic markers in NSCLC have also been discovered. These proteomics biomarkers may help to pair the individual NSCLC patient with the best treatment option. Despite the fact that implementation of these biomarkers in the clinic appears to be scarce, the recently launched Precision Medicine Initiative may encourage their translation into clinical practice.

[1]  W. Cho,et al.  Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis , 2010, British Journal of Cancer.

[2]  W. Cho.  Proteome profiling for the identification of lung cancer signatures , 2011, Expert review of proteomics.

[3]  A. Moreira,et al.  Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. , 2012, Clinical lung cancer.

[4]  W. Cho.  [Proteome profiling for the identification of lung cancer signatures]. , 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[5]  A. Heck,et al.  Next-generation proteomics: towards an integrative view of proteome dynamics , 2012, Nature Reviews Genetics.

[6]  P. Pauwels,et al.  Liquid biopsies in lung cancer: the new ambrosia of researchers. , 2014, Biochimica et biophysica acta.

[7]  A. Otto,et al.  Quantitative proteomics in the field of microbiology , 2014, Proteomics.

[8]  Jun Zhao,et al.  Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2014, Journal of cancer research and therapeutics.

[9]  G. Omenn.  Plasma proteomics, the Human Proteome Project, and cancer-associated alternative splice variant proteins. , 2014, Biochimica et biophysica acta.

[10]  Ying Jiang,et al.  The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer , 2015, Chinese journal of cancer.

[11]  Zhiyuan Hu,et al.  Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane. , 2015, ACS nano.

[12]  Yan Pan,et al.  Enoxaparin Sensitizes Human Non–Small-Cell Lung Carcinomas to Gefitinib by Inhibiting DOCK1 Expression, Vimentin Phosphorylation, and Akt Activation , 2015, Molecular Pharmacology.

[13]  H. Dienemann,et al.  Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles , 2015, International journal of cancer.

[14]  Evelyne Maes,et al.  Translating clinical proteomics: the importance of study design , 2015, Expert review of proteomics.

[15]  Chia-Wei Hsu,et al.  In-depth Proteomic Analysis of Six Types of Exudative Pleural Effusions for Nonsmall Cell Lung Cancer Biomarker Discovery* , 2015, Molecular & Cellular Proteomics.

[16]  Heiner Koch,et al.  Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. , 2015, Journal of proteome research.

[17]  Michael J. Walker,et al.  Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value , 2015, EBioMedicine.

[18]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[19]  Yu Qin,et al.  Ku80 cooperates with CBP to promote COX-2 expression and tumor growth , 2015, Oncotarget.

[20]  Arunangshu Das,et al.  Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung , 2015, Proteomics.

[21]  M. Saegusa,et al.  Calnexin is a novel sero-diagnostic marker for lung cancer. , 2015, Lung cancer.

[22]  Yu-Sun Chang,et al.  Quantitative proteomics reveals a novel role of karyopherin alpha 2 in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer. , 2015, Journal of proteome research.

[23]  T. Geiger,et al.  Super-SILAC: current trends and future perspectives , 2015, Expert review of proteomics.

[24]  S. Gygi,et al.  Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4. , 2015, Journal of proteome research.

[25]  E. Ruíz-García,et al.  Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non‐small cells lung cancer to chemotherapy , 2016, Proteomics. Clinical applications.